CLOVNasdaqHospital & Medical Service PlansFiscal year ends December 31
CLOVER HEALTH INVESTMENTS, CORP. /DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$4.44−0.04 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $2.42B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
–
Operating margin
-4.4%+9.3 pts over 5 years
Net margin
-4.4%+15.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +40.3% | +20.6% | +23.4% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 44.2% | -26.3% | |
| Return on assets | – | -102.0% | -15.3% | |
| Current ratio | – | 1.16 | 1.47 | |
| Debt to equity | – | -0.21 | – | |
| Net debt to EBITDA | – | -0.38× | – | |
| Interest coverage | – | -2.6× | – | |
| Capex to revenue | – | 0.1% | 0.1% | |
| Diluted shares | – | 89M | 512M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Clover Health Investments generated $732.69M from operations and spent $29.59M on capital expenditure, dividends and share buybacks. 32% of that went back into the business.
Generated
$732.69M
Used
$29.59M
Capital expenditure$9.37M32%Dividends$00%Share buybacks$20.22M68%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.4%
×Asset turnover3.43×
×Equity multiplier1.73×
=Return on equity, FY2025-26.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.4% | 3.43× | 1.73× | -26.3% |
| FY2022 | -31.0% | 1.25× | 1.97× | -76.1% |
| FY2021 | -39.9% | 2.42× | -14.91× | 1439.1% |
| FY2020 | -20.3% | 5.03× | -0.43× | 44.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$85.55M
- Cash generatingOperating cash flow above zero-$66.93M
- Return on assets improvedROA up on the prior year-7.5% → -14.7%
- Earnings backed by cashOperating cash flow above net income-$66.93M vs -$85.55M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.61 → 1.47
- No dilutionShare count did not rise490M → 512M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose2.40 → 3.31